Literature DB >> 6982310

Early onset of the "on-off" phenomenon in children with symptomatic Parkinsonism.

A E Lang, J C Meadows, J D Parkes, C D Marsden.   

Abstract

Many patients with idiopathic Parkinson's disease treated with levodopa for more than five years develop fluctuations in their clinical response to this drug. Such fluctuations may be unpredictable, but more commonly occur in a regular pattern related to the size and timing of the levodopa dosage. Theories as to their cause have emphasised both the progression of the underlying Parkinson's disease and the possibility of a late side-effect of levodopa. We report two children with Parkinsonism, one after recurrent obstructive hydrocephalus and the other following an encephalitic illness. Both patients had striking improvement with levodopa, but developed predictable and unpredictable dramatic response fluctuations within weeks of starting levodopa therapy. This suggests that neither the pathology of idiopathic Parkinson's disease, nor the long-term use of levodopa are essential for the development of predictable or unpredictable fluctuations in response to levodopa therapy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6982310      PMCID: PMC491565          DOI: 10.1136/jnnp.45.9.823

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  9 in total

1.  Effects of L-dopa metabolites at a dopamine receptor suggest a basis for 'on-off' effect in Parkinson's disease.

Authors:  D Dougan; D Wade; P Mearrick
Journal:  Nature       Date:  1975-03-06       Impact factor: 49.962

2.  Injected apomorphine and orally administered levodopa in Parkinsonism.

Authors:  S E Düby; G C Cotzias; P S Papavasiliou; W H Lawrence
Journal:  Arch Neurol       Date:  1972-12

3.  Paralysis agitans of early onset with marked diurnal fluctuation of symptoms.

Authors:  Y Yamamura; I Sobue; K Ando; M Iida; T Yanagi
Journal:  Neurology       Date:  1973-03       Impact factor: 9.910

4.  On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients.

Authors:  I Shoulson; G A Glaubiger; T N Chase
Journal:  Neurology       Date:  1975-12       Impact factor: 9.910

5.  Receptor basis for dopaminergic supersensitivity in Parkinson's disease.

Authors:  T Lee; P Seeman; A Rajput; I J Farley; O Hornykiewicz
Journal:  Nature       Date:  1978-05-04       Impact factor: 49.962

6.  Familial juvenile Parkinsonism.

Authors:  G Carlier; J M Dubru
Journal:  Acta Paediatr Belg       Date:  1979 Apr-Jun

7.  Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy.

Authors:  R P Lesser; S Fahn; S R Snider; L J Cote; W P Isgreen; R E Barrett
Journal:  Neurology       Date:  1979-09       Impact factor: 9.910

8.  Plasma DOPA and growth hormone in parkinsonism: oscillations in symptoms.

Authors:  P S Papavasiliou; F H McDowell; Y Y Wang; V Rosal; S T Miller
Journal:  Neurology       Date:  1979-02       Impact factor: 9.910

9.  Evidence to support early levodopa therapy in Parkinson disease.

Authors:  C H Markham; S G Diamond
Journal:  Neurology       Date:  1981-02       Impact factor: 9.910

  9 in total
  4 in total

1.  The dopaminergic response in multiple system atrophy.

Authors:  A J Hughes; C Colosimo; B Kleedorfer; S E Daniel; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

2.  Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.

Authors:  A Colzi; K Turner; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

3.  Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.

Authors:  M W Horstink; J C Zijlmans; J W Pasman; H J Berger; M A van't Hof
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-03       Impact factor: 10.154

4.  How far can I reach? The perception of upper body action capabilities in Parkinson's disease.

Authors:  Megan Rose Readman; Neil M McLatchie; Ellen Poliakoff; Trevor J Crawford; Sally A Linkenauger
Journal:  Atten Percept Psychophys       Date:  2021-07-06       Impact factor: 2.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.